Optimizing Treatment with Drug Monitoring in Adults with Metastatic Renal Cell Carcinoma
Led by Niels Fristrup · Updated on 2026-05-04
200
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to understand how monitoring the levels of cancer treatment drugs in the blood can help improve outcomes for patients with metastatic renal cell carcinoma mRCC. It focuses on how drug levels relate to treatment effectiveness and side effects, and also studies the role of antibodies and genetic variations in patients receiving checkpoint immunotherapy CPI. The study also explores how the microbiome and certain gene polymorphisms may affect treatment response and survival.
Patients with mRCC treated with drugs such as axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib, ipilimumab, and nivolumab will be observed. Blood samples will be collected regularly over six months for those on tyrosine kinase inhibitors TKIs, while CPI-treated patients will have blood and stool samples taken from the start of treatment up to two years or until treatment failure. These samples will be analyzed for drug concentrations, antibodies, genetic markers, and microbiome characteristics.
Participants will have various assessments including overall survival, progression-free survival, and quality of life measured using the FKSI-19 questionnaire over a 12-month follow-up. Researchers will track drug levels, antibody development, genetic variations, microbiome profiles, and circulating tumor DNA as markers of disease activity and treatment response. This observational study will follow Danish patients over a seven-year period to gather detailed data to better tailor treatments and improve patient care.
CONDITIONS
Brief Title
TDM for Optimized Outcome in Patients With mRCC.
Research Team
N
Niels Fristrup, MD, PhD
J
Jakob N Henriksen, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients in Denmark with medically treated metastatic renal cell carcinoma.
You will not qualify if you...
No written informed consent.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 12 months
Participants are observed while receiving medical treatment for metastatic renal cell carcinoma with drugs including axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib, ipilimumab, and nivolumab. Blood samples and fecal swaps are collected to measure drug plasma concentrations, antidrug antibodies, genetic polymorphisms, microbiome composition, and circulating tumor DNA.
Blood samples and assessments at each clinical visit during treatment; fecal swaps during treatment; 12 months follow-up
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Using 3D Ultrasound Imaging to Guide Ablation or Biopsy Treatment for Liver and Kidney Tumors
Study of HC-7366 Combined With Nivolumab With or Without Ipilimumab in Advanced Kidney Cancer
Study of OM-RCA-01 Antibody for Safety and Effectiveness in Treating Metastatic Cancers with FGFR1
Study of Shared Decision Making Tools for Patients with Renal Cell Carcinoma to Improve Treatment Choices
I CARE Trial Evaluating a Navigation Program to Support Diverse Cancer Patients
Using Immunotherapy and Its Impact on Treatment Continuation
Phase 1 Study of JMKX003948 Tablets to Evaluate Safety and Preliminary Effectiveness in Adults with Advanced Renal Cell Carcinoma
Phase 1b2a Study to Evaluate Safety and Effectiveness of Oral Alintegimod with Ipilimumab Followed by Nivolumab in Adults with Advanced or Metastatic Solid Tumors
Evaluating Sasanlimab, Palbociclib, and Axitinib Treatment in Advanced Metastatic Renal Cell Carcinoma
Patient Preference Study Comparing Subcutaneous and Intravenous Immune Checkpoint Inhibitors
and Care Delivery Methods for Renal Cell Carcinoma
Phase 1 Study of VET3-TGI Alone and With Atezolizumab for Advanced Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol.
Jakob N Henriksen, Charlotte U Andersen, Frede Donskov...